Agilent Technologies, Inc.
A Healthcare Diagnostics & Research
Agilent Technologies, Inc.’s revenue for fiscal 2025 (year ended October 2025) was $6.9 billion, up 6.73% from fiscal 2024. In the quarter to July 2026, revenue grew 8.06%, EPS grew 8.47%, free cash flow grew 69.5% and total debt rose 8.81%, each against the same quarter a year earlier. Member of the S&P 500; dividend growth for ten consecutive years.
Follow A
Agilent Technologies, Inc. (A) Return on assets
Agilent Technologies, Inc.'s return on assets over the twelve months to 31 July 2026 was 11.0%, up 0.4 percentage points from fiscal 2025 (10.6%). Over the past ten years it has ranged from 3.72% (fiscal 2018) to 11.9% (fiscal 2021); the current reading is higher than 55% of that period. That is above the Diagnostics & Research industry median of −6.71% and above the Healthcare sector median of −30.9%.
Return on assets, annual
Embed this chart
Annual newest first
| Period | Return on assets | Change (points) |
|---|---|---|
| FY2025 | 10.6% | (0.79) |
| FY2024 | 11.4% | (0.25) |
| FY2023 | 11.7% | (0.16) |
| FY2022 | 11.8% | (0.09) |
| FY2021 | 11.9% | 4.36 |
| FY2020 | 7.54% | (4.36) |
| FY2019 | 11.9% | 8.18 |
| FY2018 | 3.72% | (4.71) |
| FY2017 | 8.43% | 2.38 |
| FY2016 | 6.05% | 1.67 |
Against its own ten years
Return on assets against peers
| Company | Return on assets |
|---|---|
| IDXX IDEXX Laboratories, Inc. compare | 33.7% |
| MTD Mettler-Toledo International, Inc. compare | 25.6% |
| ILMN Illumina, Inc. compare | 13.0% |
| A Agilent Technologies, Inc. | 11.0% |
| DGX Quest Diagnostics Incorporated compare | 6.43% |
| LH Labcorp Holdings Inc. compare | 5.48% |
| IQV IQVIA Holdings Inc. compare | 4.70% |
| WAT Waters Corporation compare | 1.13% |
| NTRA Natera, Inc. compare | −8.71% |
| Diagnostics & Research industry median | −6.71% |
| Healthcare sector median | −30.9% |
| Market median | 0.00% |
What Return on assets is
ROA tells an investor how much profit a company earns for shareholders from the assets it uses to run its business.
Annual: Net Income Allotted to Shareholders ÷ Average Assets; TTM: Net Income Allotted to Shareholders ÷ Average Assets (latest quarter)
More on A
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement